Unknown

Dataset Information

0

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.


ABSTRACT: Based on clinical presentation, glioblastoma (GBM) is stratified into primary and secondary types. The protein 53 (p53) pathway is functionally incapacitated in most GBMs by distinctive type-specific mechanisms. To model human gliomagenesis, we used a GFAP-HRas(V12) mouse model crossed into the p53ER(TAM) background, such that either one or both copies of endogenous p53 is replaced by a conditional p53ER(TAM) allele. The p53ER(TAM) protein can be toggled reversibly in vivo between wild-type and inactive conformations by administration or withdrawal of 4-hydroxytamoxifen (4-OHT), respectively. Surprisingly, gliomas that develop in GFAP-HRas(V12);p53(+/KI) mice abrogate the p53 pathway by mutating p19(ARF)/MDM2 while retaining wild-type p53 allele. Consequently, such tumors are unaffected by restoration of their p53ER(TAM) allele. By contrast, gliomas arising in GFAP-HRas(V12);p53(KI/KI) mice develop in the absence of functional p53. Such tumors retain a functional p19(ARF)/MDM2-signaling pathway, and restoration of p53ER(TAM) allele triggers p53-tumor-suppressor activity. Congruently, growth inhibition upon normalization of mutant p53 by a small molecule, Prima-1, in human GBM cultures also requires p14(ARF)/MDM2 functionality. Notably, the antitumoral efficacy of p53 restoration in tumor-bearing GFAP-HRas(V12);p53(KI/KI) animals depends on the duration and frequency of p53 restoration. Thus, intermittent exposure to p53ER(TAM) activity mitigated the selective pressure to inactivate the p19(ARF)/MDM2/p53 pathway as a means of resistance, extending progression-free survival. Our results suggest that intermittent dosing regimes of drugs that restore wild-type tumor-suppressor function onto mutant, inactive p53 proteins will prove to be more efficacious than traditional chronic dosing by similarly reducing adaptive resistance.

SUBMITTER: Shchors K 

PROVIDER: S-EPMC3631679 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

Shchors Ksenya K   Persson Anders I AI   Rostker Fanya F   Tihan Tarik T   Lyubynska Natalya N   Li Nan N   Swigart Lamorna Brown LB   Berger Mitchel S MS   Hanahan Douglas D   Weiss William A WA   Evan Gerard I GI  

Proceedings of the National Academy of Sciences of the United States of America 20130329 16


Based on clinical presentation, glioblastoma (GBM) is stratified into primary and secondary types. The protein 53 (p53) pathway is functionally incapacitated in most GBMs by distinctive type-specific mechanisms. To model human gliomagenesis, we used a GFAP-HRas(V12) mouse model crossed into the p53ER(TAM) background, such that either one or both copies of endogenous p53 is replaced by a conditional p53ER(TAM) allele. The p53ER(TAM) protein can be toggled reversibly in vivo between wild-type and  ...[more]

Similar Datasets

| S-EPMC3060664 | biostudies-literature
| S-ECPF-GEOD-22927 | biostudies-other
| S-ECPF-GEOD-33331 | biostudies-other
2011-10-31 | GSE33331 | GEO
2011-03-23 | GSE22927 | GEO
2011-10-31 | E-GEOD-33331 | biostudies-arrayexpress
2011-03-23 | E-GEOD-22927 | biostudies-arrayexpress
| S-EPMC9202004 | biostudies-literature
| S-EPMC4282994 | biostudies-literature
| S-EPMC10762395 | biostudies-literature